Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 3/20 | 0.42 |
| ▸ | CCR9 | P51686 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5673746 | 0.89 | KAT6A (0.45) | KAT6ACCR9FFAR4LMNAHTT | |
| SCHEMBL12051676 | 0.86 | KAT6A (0.47) | KAT6ACCR9FFAR4LMNAHTT | |
| SCHEMBL13077856 | 0.86 | FFAR4 (0.50) | KAT6ACCR9FFAR4LMNAHTT | |
| SCHEMBL28860 | 0.86 | KAT6A (0.45) | KAT6ACCR9FFAR4LMNAHTT | |
| SCHEMBL12051671 | 0.85 | KAT6A (0.43) | KAT6ACCR9FFAR4LMNAHTT | |
| SCHEMBL28400 | 0.85 | CCR9 (0.52) | KAT6ACCR9FFAR4LMNAHTT | |
| SCHEMBL29408 | 0.85 | MEN1 (0.47) | KAT6ACCR9FFAR4LMNAHTT | |
| SCHEMBL5673759 | 0.85 | ALDH1A1 (0.41) | KAT6ACCR9FFAR4LMNAHTT | |
| SCHEMBL27773 | 0.84 | CCR9 (0.46) | KAT6ACCR9FFAR4LMNAHTT | |
| SCHEMBL12051672 | 0.83 | KAT6A (0.43) | KAT6ACCR9FFAR4LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999109-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7820717-B2 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100093802-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNNIUM PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20090054495-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | disclosed |
| US-20080103180-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093802-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | KAT6A 3501/4885CCR9 1/4885FFAR4 1465/4885 |
| US-20090054495-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | KAT6A 3501/4885CCR9 1/4885FFAR4 1465/4885 |
| US-20080103180-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | KAT6A 3501/4885CCR9 1/4885FFAR4 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.